Science topic

Cancer Prevention - Science topic

A forum for debate and questions regarding cancer prevention.
Questions related to Cancer Prevention
  • asked a question related to Cancer Prevention
Question
3 answers
Press release, 22 October 2024
Understanding the physics of cancer, preventing metastases: Leopoldina honours the physician Bahriye Aktas and the biophysicists Jochen Guck and Josef Käs with the Greve Prize
Dealing with metastases is one of the major challenges of cancer therapy. More than 90 percent of deaths caused by cancer are linked to metastases. Understanding the conditions that cause cancer metastases and how these move through the body is key to developing new approaches to cancer treatment. Biophysics can provide valuable insights, as cancer is also subject to the laws of physics. In honour of their groundbreaking insights into the movement of tumour cells, the physician Professor Dr Bahriye Aktas, and the biophysicists Professor Dr Jochen Guck, and Professor Dr Josef Käs are receiving the 2024 Greve Prize from the German National Academy of Sciences Leopoldina. The award, endowed with 250,000 euros, is donated by the Helmut and Hannelore Greve Foundation for Science, Development and Culture.
The biophysicist Professor Dr Josef Käs from the University of Leipzig/Germany and Professor Dr Jochen Guck from the Max Planck Institute for the Physics of Light in Erlangen/Germany are leading global scientists in the physics of cancer. Their research, some of which they have conducted jointly, investigates the physical properties of cells when they interact with surrounding tissue. They have managed to demonstrate how tumour cells actively change from solid and stiff to a fluid and soft condition in order to move between the dense tissue of the human body and form metastases. This discovery has led to a paradigmatic shift in how cancer cells are viewed and motivated collaboration with the physician Professor Dr Bahriye Aktas from the University of Leipzig Medical Center. Aktas has made it possible to study human tumour samples directly after operating and thus also live-cell microscopy of the active deformation of cancer cells. Building on the work of their predecessor Professor Dr Michael Höckel, this raises the question of what limits cancer cells in the body experience. “Bahriye Aktas, Jochen Guck, and Josef Käs provide an impressive example of how interdisciplinary basic research can significantly deepen the understanding of cancerous diseases,” says Leopoldina President Professor (ETHZ) Dr Gerald Haug. “Studying the behaviour of tumour cells from the perspective of physics and linking it to direct insights gained from medical institutions has the potential to develop completely new means of treating cancer.”
The potential for cancer treatment is already apparent with respect to breast cancer. Whether the cancer has metastasised or not is key in determining the success of therapies. To date, however, it has not been possible to accurately predict when a tumour forms metastases. Käs and Aktas, working together with Professor Dr Axel Niendorf (Hamburg/Germany), managed to identify markers that, in combination with existing criteria, are significantly better at indicating a tumour’s potential to metastasise. They have done so using biophysical concepts, the central idea of which – that metastasising cancer cells must be softer – Jochen Guck played an important role in developing. Cancer cells in primary tumours are, at the local level, very solid and densely packed. In order to release themselves from the original tumour and move through the human body, cancer cells must soften, allowing the cancer cell aggregate to become fluid. In the study carried out by Käs and Aktas together with Axel Niendorf, the scientists identified the histological characteristics of the cancer cells that become fluid: they were longer and had deformed cell nuclei, allowing them to “squeeze” through neighbouring tissue. Their study of more than 1,000 breast cancer patients offers a strong indication that these deformed cell and nuclei forms can be used as a reliable marker for a cancer’s aggressiveness, and to predict a tumour’s potential to metastasise. This could permit breast cancer treatments to be more individually tailored to patients. In Erlangen, parallel to the activities in Leipzig, Guck developed a high-throughput method to measure the deformability of cells (real-time deformability cytometry, RT-DC). This method is particularly suited to finding substances that can change cancer cell mechanics to prevent metastases.
Bahriye Aktas (born in 1975) is Professor of Gynaecology at the University of Leipzig and Director of the Department of Gynaecology at the Leipzig Medical Center. Aktas studied medicine at the Justus Liebig University Gießen/Germany. She completed her medical training as a gynaecologist and obstetrician at the University Hospital Essen/Germany, obtained her habilitation there in 2013, and was appointed Associate Professor in 2017. That year she switched to the University of Leipzig. As a gynaecologist, her focus is on minimally invasive and robot-assisted surgery, which is used for gentler and precise operations with improved chances of healing, and she also has a particular interest in surgery for cancer treatment. She and her predecessor have helped to globally establish new operation methods that take into account how a tumour spreads.
Relevant answer
Recent advances in the physics of cancer have led to significant progress in understanding and treating metastases, particularly through emerging radiotherapy techniques, let me talk about this. One notable development is stereotactic body radiation therapy (SBRT), which delivers highly focused, high-dose radiation to small tumors with extreme precision. As we know, this modality has shown promising results in treating oligometastatic disease, where cancer has spread to a limited number of sites.Another emerging approach is proton beam therapy, which uses charged particles to deliver radiation more precisely to tumors while sparing surrounding healthy tissue. This is particularly beneficial for treating metastases in sensitive areas like the brain or spine.Adaptive radiotherapy is gaining action, especilly for oART, using real-time imaging to adjust treatment plans based on changes in tumor size and position during the course of therapy. This allows for more accurate targeting of metastatic lesions.MRI-guided radiotherapy is another innovative technique, combining high-quality soft-tissue imaging with radiation delivery. This enables better visualization and targeting of metastases, especially in areas with complex anatomy.Lastly, researchers are exploring the combination of radiotherapy with immuno, leveraging radiation's ability to enhance the immune response against cancer cells. This approach, known as radioimmunotherapy, shows promise in treating widespread metastatic disease by potentially creating a systemic anti-tumor effect.These advancements in radiotherapy techniques offer new hope for patients with metastatic cancer, potentially improving outcomes and quality of life. In a nutsell, we have to be optimisitc about physics applied to cancer especially due to radiotherapy.
  • asked a question related to Cancer Prevention
Question
21 answers
A 35 years old lady, a known case of Psoriasis is on Homeopathic treatment. She has been married for the last 2 years and has now reported for evaluation for infertility. She has normal menstrual periods. Her general, systemic and pelvic examinations are within normal limits except for psoriatic patches. Laboratory investigations are normal. On pelvic USG, uterus is normal size and endomyomtrial echotexture is normal. There are 2 small subserous fibroids, one small cyst in right adnexa adjacent to ovary (? parovarian cyst) and an endometrial polyp of 13 x 8 mm size. Planning for hysteroscopic polypectomy. Can one go ahead with laparohysteroscpic evaluation in this case along with polypectomy?
Relevant answer
Answer
In a case of infertility where an endometrial polyp has been detected on pelvic ultrasound, the initial management typically involves a multidisciplinary approach involving both gynecologists and infertility specialists. Here's a general outline of the initial management:
Confirmation of Diagnosis: Confirm endometrial polyp through imaging or diagnostic procedures like hysteroscopy or SIS.
Evaluation of Infertility: Assess other factors contributing to infertility in both partners.
Assessment of Hormonal Status: Check hormone levels to understand hormonal imbalances.
Treatment Options:
Medical Management: Hormonal therapy to regulate cycles and shrink the polyp.
Surgical Removal: Polypectomy via hysteroscopy for large or symptomatic polyps.
Fertility Treatments: Consider IUI or IVF, with or without polyp removal.
Follow-Up: Regular appointments to monitor response, assess recurrence, and evaluate treatment effectiveness.
Address Other Contributing Factors: Identify and address any additional factors affecting infertility.
Lifestyle Modifications: Encourage healthy habits like weight management, stress reduction, and smoking cessation.
  • asked a question related to Cancer Prevention
Question
2 answers
Dear Researchers:
Could you please share some simple cures or prevention for COVID-19, Cold, Flu or Influenza, and possibly Other Viruses, and Cancers?
Updates on Oct. 10, 2023: First, many thanks to all contributors to this discussion. Here are some Natural Approaches found from surveying literature in medicine to Boost our Immune Systems against viruses such as COVID-19, Cold, Flu or Influenza infections and to avoid/minimize developing further inflammations in the lungs and hearts caused by some of those viruses:
Give it a try, please! Especially if you increase your Vitamin D level to a required level and consume Vitamin C sources, e.g., oranges, on a daily basis, you can check how rarely you would catch the virus. Or, even after catching the virus, the virus will likely develop very mild symptoms in your body.
1- Daily uptake of Vitamin D pills up to 100 IU per 1 kg weight is safe and very important, recommended by Afshar et al. (2000) and Dr. Hamid Sajjadi in an interview, to RAISE the Vitamin D level in our body to the POINT which is REQUIRED to BOOST our IMMUNE SYSTEMS against Viruses and Diseases including Cancers.
Vitamin D daily use needs to be adjusted based on our body weight.
Please read the following article by Afshar et al. (2000) about the importance of vitamin D and the required daily dose of it (Up to 100 IU per 1 kg weight) to boost our Immune Systems.
Please also read the following Review article by Jordan et al. (2022) about the importance of Vitamin D on the level of infection & disease progression for COVID-19. You may find in the article the importance of our Forgotten SUN.
Vitamin D is rarely available in food sources, except in fatty fish which needs to be eaten high enough to get the required amount of Vitamin D for a body.
Another good natural source is daily sunbathing with naked skin; however, in cloudy regions such as Europe, sunbathing doesn't work well.
Vitamin D helps to absorb Calcium in our intestines and thus, in order to avoid excessive absorption of Calcium by our body, it would be better to use Vitamin D pills with Calcium sources such as warmed-up milk and Magnesium sources such as bananas on a daily basis. Because magnesium competes with calcium in our intestines to get absorbed.
Here is a text from A Review article by Kulie et al. (2009) about some of the importance of Vitamin D on our health:
"Vitamin D is a fat-soluble vitamin that plays an important role in Bone Metabolism and seems to have some Anti-Inflammatory and Immune-Modulating properties. In addition, recent epidemiologic studies have observed relationships between low vitamin D levels and multiple disease states.
Low vitamin D levels are associated with increased overall and Cardiovascular mortality, Cancer incidence and mortality, and Autoimmune Diseases such as Multiple Sclerosis. Although it is well known that the combination of vitamin D and calcium is necessary to maintain Bone Density as people age, vitamin D may also be an independent risk factor for falls among the Elderly."
2- Having Good Nutrients including Protein sources, Minerals, and Other Vitamins, e.g., C, A, and E, sources from fresh fruits, vegetables, and nuts. For example, the good sources of fruits and vegetables for these vitamins could be a daily use of 1-2 Oranges for Vitamin C, Carrots for Vitamin A, and Almonds or Sunflower Seeds for Vitamin E.
As Vitamin C is a water-soluble vitamin, the excess of it will be excreted from the body, it needs to be consumed every day to provide everyday vitamin C requirements for the body, as it is the 2nd most important vitamin after Vitamin D to boost our Immune Systems against viruses and diseases.
And, Vitamin B family from grains, poultry, and meat sources.
3- After the infection by those viruses, gargling salty water to disinfect the throat to avoid further movement of the virus into the lungs as the virus may stay in the throat for a few days
4- Inhaling Steamed Fresh Leaves, if not available, the Oil, of Eucalyptus 4-5 times a day for several continuous days to kill the virus in the lungs.
Here is A Review article by Mieres-Castro et al. (2021) about the "Antiviral Activities of Eucalyptus Essential Oils: Their Effectiveness as Therapeutic Targets against Human Viruses"
Australian Aboriginals are very much using Eucalyptus to Treat Infections.
5- Having plenty of Warm Drinks to wash out the virus from our body and dilute the blood to avoid blood clotting.
6- Having enough sleep and daily activities/exercises
7- Kids are proven to have High Immunity Against COVID-19, likely due to having a high amount of Melatonin, the Sleep Hormone, in their blood. So, that is why kids sleep very much as you know.
Melatonin production in our body usually decreases with increasing age. Thus, we may use daily melatonin pills after the infection based on what physicians may prescribe for us.
Here is A Review article by Carrillo-Vico et al. (2013) about the Importance of Melatonin on the Functionality of Our Immune Systems:
8- Avoid Fear/Panic as it Substantially Deteriorates the Functionality of Immune Systems against viruses and diseases.
Here is an interview by Dr. Lauren Deville about How Fear Affects Our Immune System:
Relevant answer
Many thanks, Rohan RANJAN Waliya, for contributing to this discussion!
  • asked a question related to Cancer Prevention
Question
4 answers
Exercise can impact cancer prevention through various mechanisms but its unclear on which extent it works.
Kindly highlights some points related to this.
Relevant answer
Answer
Dear Habiba,
Staying active makes your body more healthy and your immunity will work better which is essential for preventing genetic component, for example mutations in tumours suppressor genes. Take a look at our research because we analysed correlation between life styles and development of the breast cancer.
Sincerely,
Amar, MSc in MLT
  • asked a question related to Cancer Prevention
Question
11 answers
can we treat breast cancer with vitamin d?
Relevant answer
Answer
Also see the following useful link for more insight.
  • asked a question related to Cancer Prevention
Question
3 answers
In addition to the beneficial effects on oxidative stress, cardiovascular health, nervous system diseases, aging, and cancer prevention, cocoa has been revealed as a food with immunoregulatory properties; a remarkable effect on the immune system. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3671179/
Dark chocolate contains a higher amount of phytochemicals than milk or white chocolate do and is linked to reducing inflammation in the body; it may reduce the severity of symptoms associated with arthritis. The key is consuming foods with a high cocoa content, ideally 70 % or higher.
Chocolate is an energy-dense food and could easily contribute to weight gain if you over-consume it so carefully enjoy the health benefits of chocolate in moderation.
An interesting discussion by a group of Rheumatology doctors and patients has been raised on this matter too.
Relevant answer
Beneficios del chocolate
  • asked a question related to Cancer Prevention
Question
1 answer
My investigation is related to measures countries (Mexico for example) have taken focusing on lung cancer prevention, considering sustainable environmental policies.
Relevant answer
Answer
First step - close all tobacco companies.
Second step - smoking is not allowed.
  • asked a question related to Cancer Prevention
Question
2 answers
"In chronic inflammation, IL-6 has a detrimental role that favours mononuclear cell accumulation at the site of injury, through continuous MCP-1 secretion, angioproliferation and anti-apoptotic functions on T cells [30]. This may increase serum levels of IL-6 and provide the basis for the amplification step of chronic inflammatory proliferation."
Interleukin-6 is released by monocytes and macrophages in response to other inflammatory cytokines which include interleukin-11, and tumor necrosis factor (TNF)-beta.
"Chronic inflammation can result from the following:
  1. Failure of eliminating the agent causing an acute inflammation such as infectious organisms including Mycobacterium tuberculosis, protozoa, fungi, and other parasites that can resist host defenses and remain in the tissue for an extended period.
  2. Exposure to a low level of a particular irritant or foreign materials that cannot be eliminated by enzymatic breakdown or phagocytosis in the body including substances or industrial chemical that can be inhaled over a long period, for example, silica dust.
  3. An autoimmune disorder in which the immune system is sensitized to the normal component of the body and attacks healthy tissue giving rise to diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE).
  4. Recurrent episodes of acute inflammation. However, in some cases, chronic inflammation is an independent response and not a sequel to acute inflammation for example diseases such as tuberculosis and rheumatoid arthritis.
  5. Inflammatory and biochemical inducers are causing oxidative stress and mitochondrial dysfunction such as increased production of free radical molecules, advanced glycation end products (AGEs), uric acid (urate) crystals, oxidized lipoproteins, homocysteine, and others."
Cytokine Panel (ARUP):
Interleukin 2 Receptor (CD25) Soluble
Interleukin 12
Interferon gamma
Interleukin 4
Interleukin 5
Interleukin 10
Interleukin 13
Interleukin 1 beta
Interleukin 6
Interleukin 8
Tumor Necrosis Factor - alpha
Interleukin 2
Interleukin 17
Question:
If CRC patients had a hair sample analyzed for fungal cultures, what fungi would be found?
Relevant answer
Answer
Bogdan Socea Thanks for sharing - I agree!
  • asked a question related to Cancer Prevention
Question
6 answers
The event of death by metastasis or recurrence is very common, many researchers have linked the tendency of some tumors to re-appear to the presence of occult or dormant cancer cells that may have a phenotype that allows them to remain "hidden" from the immune response. However, the understanding of these cells and the mechanisms that they use to achieve evasion remain mostly unknown. It is critical to understand these cells better and to be able to detect their presence for they are of great therapeutic importance.
Relevant answer
Answer
Hi
LGR5 is the best biomarker for detection of cancer stem cells in colorectal patients .
u can browse our my profile and see our paper about that
Regards
  • asked a question related to Cancer Prevention
Question
9 answers
Dear Sir/Madam, I invited as a guest editor from high quality journals to handle special issues. If anyone can prepare a review similar to my review papers, particularly about a natural product in cancer prevention with focus on the structure activity relationship and mechanism of action, please kindly let me know to send an official letter. At this stage you should just send the title, authors and affiliation and abstract. Please kindly let me know as soon as you can. The suggested deadline for sending review is about 3 month. Best wishes, Suggeted topic: Genotoxicity of different agents and possble protection. Reducing side effects of radiotherapy and chomotherapy. Next generation of cancer therapy; Natural products. Natural products as novel therapeutic compounds. Radiation protection.
Relevant answer
Answer
What is names of the journals
  • asked a question related to Cancer Prevention
Question
15 answers
We sequenced the exons of some healthy persons, and we know that some of them run the risk of developing cancers. Is it feasible to develop preventive cancer vaccines? The vaccines would secure them from developing lung cancer, liver cancer, etc. Thanks.
Relevant answer
Answer
Please take a look at these useful PDF attachments.
  • asked a question related to Cancer Prevention
Question
8 answers
There are a lot of published data that showed association between vitD deficiency and many disorders e.g. diabetes, metabolic syndrome, CVD, cancer,...
Relevant answer
Answer
Please see the following PDF attachment.
  • asked a question related to Cancer Prevention
Question
6 answers
We are listening an uninterrupted flow of screening aand treatament of breast cancer, but neve-ever of primary prevention of breast cancer, before the signs of the disease appear. What is wrong with the public health system and polict?
Relevant answer
Answer
Flax seed reduces the growth of tumors in patients with breast cancer, mainly postmenopausal women. Therefore, eating flax seeds every day lowers the risk of breast cancer.
  • asked a question related to Cancer Prevention
Question
7 answers
Treatment for Cancer nowaydays like surgery and chemotherapy is really expensive for majority Cancer pasien in Indonesia, exspecially at Borneo. Can Cancer be cured with any methods that not too expensive but effective and efficient? 
Relevant answer
Answer
I have previously responded to a similar question on this platform. Please see the below given RG link.
Thanks!
  • asked a question related to Cancer Prevention
Question
4 answers
Phytonutrients properties of functional foods against colon cancer-inducing agents, such as azoxymethane, in animal models
Relevant answer
  • asked a question related to Cancer Prevention
Question
4 answers
Vitamin D inhibits prostaglandins associated with cancer in serum and nipple aspirate fluid.
Relevant answer
Answer
Data has shown that women with low levels of the vitamin are at higher risk for developing the cancer. But there isn't enough evidence yet to directly link high levels of vitamin D to a decreased risk for breast cancer. .
  • asked a question related to Cancer Prevention
Question
14 answers
Hi,
Greetings!
Lifestyle modification can bring down the incidence of cancer, improve prognosis and quality of life in cancer survivors.
Can you please share your opinion or experience in implementing Lifestyle medicine in cancer prevention and prognosis.
Relevant answer
Answer
hi I'm GP at Monash medical clinic( Caulfield campus)
I'm doing my Lifestyle medicine board exam in Auckland this week ( Australasian Society of lifestyle medicine )
There is plenty Evidence based facts to support need for reinforcing lifestyle education/change in almost every GP consultation.There is also big need to educate medical students and all medical professionals about the importance of this easily neglected aspect of therapy .
  • asked a question related to Cancer Prevention
Question
1 answer
Briefly, the Breast and Prostate Cancer Cohort Consortium(BPC3) is a consortium of breast cancer case-control sets nested in seven cohorts: the American Cancer Society Cancer Prevention Study II (CPS-II), the European Prospective Investigation into Cancer and Nutrition Cohort (EPIC), the Multiethnic Cohort (MEC), the Nurses’ Health Study I and II (NHS and NHSII), the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), and the Women’s Health Study (WHS). But how to access this dataset.
Relevant answer
Answer
Did you try contacting Mukesh Verma and Scott Rogers?
  • asked a question related to Cancer Prevention
Question
3 answers
Dear Dr Akhtar and Dr Swamy,
I take this opportunity to introduce myself as Dr Naveen Kaushal, assistant Professor in Panjab University, Chandigarh. I had contributed a book chapter entitled "Usefulness of Ocimum sanctum Linn (Holy Basil orTulsi) in cancer prevention: An update"  alongwith Prof. Shrinath Baliga in the book  entitled  "Anticancer Plants: Properties and Applications".
However, till date we have not received any information about the status of the book/ chapter we have contributed.
Therefore, I request you to update us regarding the status of the same asap. If already published please send me the copy of the same.
Thanks and Best Regards
📷
Relevant answer
Answer
Dear Dr. Naveen,
The book is in production. I will update you soon in this matter.
With regards,
Mohd Sayeed Akhtar
  • asked a question related to Cancer Prevention
Question
10 answers
How the Ketogenic Diet Works
Intermittent Fasting and Cancer Prevention
Relevant answer
Answer
In few words. Cancer cells are fueled by glucose to activate Warburg effect (energy only through the glycolysis) If you deprive them of glucose, the metabolism should switch to ketone bodies. But cancer cells are metabolically not able to switch to ketone bodies as fuel because they can only survive on glucose. All of other cells can use either glucose or ketone bodies. Lacking this metabolic flexibility, cancer cells go in starvation.
  • asked a question related to Cancer Prevention
Question
3 answers
It is known that many of the causes of cancer are related to environmental factors (radiation, chemical contamination of water, food, air, among others) and this question intends to gather ideas for a research topic related to Finite Element Method, Computer Fluid Dynamics, Finite Differences, Continuum Mechanics, Monte Carlo and Molecular Dynamics in order to advance the knowledge in cancer prevention and treatment.
Relevant answer
Answer
Thank you Mr. Haringa and Mr. Mazur. I'll have a look at those ideas and links.
  • asked a question related to Cancer Prevention
Question
1 answer
Much thanks.
Relevant answer
Answer
I'm not sure if it will help or not.  Most of my research has been with cluster and migraine headache sufferers with vitamin D3 deficiencies.  That said, I just returned from the 20th Vitamin D Workshop in Orlando, FL.  The attendance list read like a who's who in vitamin D3 research coming from fields in molecular biology, genetics, medicine, pharmacology, epidemiology, nutrition and public health.  There were at least two cancer studies briefed with very promising results. 
What I am sure of is that screening with lab tests for 25(OH)D (Vitamin D3 status) is effective.  There's a long list of studies linking vitamin D3 deficiency with colorectal cancer.  There are also a growing number of clinical trials using vitamin D3 at therapeutic/pharmacological doses ≥ 7000 IU/day, some up to 50,000 IU three times a week to treat colorectal cancer. That's roughly 25 cents USD a day worth of vitamin D3.
If you're into gene mapping, the density of vitamin D3, (1,25(OH)2D3) receptors (VDR) are at median concentration in the colon...  See the gene atlas for the VDR gene at the following link:  http://biogps.org/#goto=genereport&id=7421
Take care,
V/R, Batch
  • asked a question related to Cancer Prevention
Question
2 answers
My compound have effect on delaying the growth rate of C.elegans, particularly on L3 and L4 stage. I want to explore the mechanism of this phenotype with the heterochronic pathway, but there is few papers related to this. 
Relevant answer
Answer
The compound you add is delaying growth. What food source do you use? If you breed your own OP50 it is not a real technical replicate and C.elegans can behave differently when being fed with varying OP50 conditions and quality. Do you breed OP50 in a controlled bioreactor?
Otherwise use LabTIE OP50 to make sure your feeding protocol does not influence the impact of the substance
More info can be found here
  • asked a question related to Cancer Prevention
Question
3 answers
Presently, I am working on breast cancer. I want to know collecting which type of sample is better to understand the disease pathogenesis.
1. Blood Sample
2. Tissue Sample
Relevant answer
Answer
Basically it depends on the mechanism of that particular disease and also the nature of specific biomarkers that you will be looking at. Some markers are high expressed in the blood circulation and some are actively produced/working in the tissue itself. Before you proceed, you may check the mechanism/pathology of that particular disease you are working on. 
  • asked a question related to Cancer Prevention
Question
1 answer
use of person-centred therapy in family counselling.
Relevant answer
Answer
I think the inner person must be the most important target in all therapies, included official Medecine (everyone knows that a person with cancer, survival is better if this person has a good psychological state). In a family crisis, every person has a role in the cridis, so, every person must be a center of a theraphy,
  • asked a question related to Cancer Prevention
Question
4 answers
Under conditions of:
Not feeling comfortable with the treatment decision?
Being diagnosed with a rare type of cancer?
Having several options for how to treat the cancer?
Not being able to see a cancer expert?
Relevant answer
Answer
 Hi Evrim,
ot only should one seek a second opinion, but also a third opinion. It is better to have a majority opinion than to have to choose between two. I would go to  and/or seek advice from a specialist in oral cancer. The specialist would want to see x-rays and any other objective data. Don't depend on one person being correct 100% of the time. I hope this helps.
Velma
  • asked a question related to Cancer Prevention
Question
3 answers
Hello researchers
In the attached table , we have 250 samples each one of them had been genotyped and diagnosed histologically to its stage of cancer .
what is the most suitable statistical method which can be used to assess if there is any kind of relationship between each genotype and cancer stage .
best regards
Relevant answer
Answer
A calculation using the attached on line calculator gives chi2 (Yates uncorrected) of 9.127 6 dof P= 0.166 and chi2 (Yates corrected) of 6.04 P= 0.416   ie no association at 5% significance  level.
  • asked a question related to Cancer Prevention
Question
2 answers
Wish I could know if HIFU ablation technique will be discussed.
Relevant answer
Answer
No I will not, because this is a conference for education of RFA
Please join enclosed following conference
This conference includes thyroid HIFU lecture
  • asked a question related to Cancer Prevention
Question
2 answers
I'm looking for an english version of the Illness Perception questionnaire - Revised Illness Perception Questionnaire for Healthy People (IPQ-RH). Thanks in advance.
Relevant answer
Answer
Hello Bianca,
These ResearchGate authors might be able to let you know if this is available:
Figueiras, M. J., & Alves, N. C. (2007). Lay perceptions of serious illnesses: An adapted version of the Revised Illness Perception Questionnaire (IPQ-R) for healthy people. Psychology and Health, 22(2), 143-158.
Petrak, A., Sherman, K. A., & Fitness, J. (2015). Validation of the Croatian and Lebanese Revised Illness Perception Questionnaires for Healthy People (IPQ‐RH). European journal of cancer care, 24(3), 355-366.
I hope you find what you need.
Very best wishes,
Mary
  • asked a question related to Cancer Prevention
Question
13 answers
A 23 years old girl has been having recurrent vaginitis for the last one year.She has been in relationship for the last few years. Barrier contraception is being used with the present partner. She used to have unprotected intercourse with the previous partner. The clinical picture is that of fungal vaginitis. Local antifungal agent, Clotrimazole (at times along with Clindamycin) have been administered few times. She was put on once a week Flucanozole tablet for 6 weeks. The couple had taken combination of Azithromycin, Flucanozole and Secnidazole few months back. GTT done recently is WNL. HIV and VDRL were done in February and repeated few days back. They are non reactive. High vaginal swab has been taken for culture. Vaginal secretions have been collected for cytology. Report is awaited. How to manage this case?
Relevant answer
Answer
The screening process has been methodical with extensive screening for STI's , Diabetes and  immune compromise undertaken. Repeat antifungals x 6 administered. Barriers are in use: Penis-vaginal transmission ruled out.
Is there another source for the vaginitis? gut and oral sources come to mind. Any information on whether cunnilingus and /or fellatio is practiced. Source/pool Identification
Suggest a medication break, diet change -try yogurt alternate day as a meal item or snack , avoid antibiotic use. How about some pro-biotics?  
  • asked a question related to Cancer Prevention
Question
5 answers
In planning a cancer education intervention, I have minor interest in assessing cancer prevention knowledge, but am much more interested in behavior.  I would like to have measures of cancer prevention behaviors that capture the wide range of risk/protective factors.  For example:
Smoking, tobacco use, (+ second-hand smoke exposure)
Moderate to vigorous physical activity and sedentary behavior 
Healthfulness of diet, including red/processed meat, fruits and vegetables, beans and legumes, whole grains, sugar-sweetened beverages, etc.
Sun protection, including shade, peak sun exposure, hats, sunscreen, etc.
Vaccination for Hepatitis B and HPV
Maintaining a healthy weight (BMI percentile)
(+ Possibly also alcohol consumption)
Is there an available validated cancer prevention index for children or adolescents that combines factors such as these into an overall score?
Is there an established and valid way to combine objective and self-report items to get an index of cancer prevention behavioral risk?
Thus far, I've found the following citation, but haven't yet seen the instrument: Melnyk BM. Healthy Lifestyles Behavior Scale. Hammondsport NY: COPE for HOPE, Inc., 2003
Relevant answer
Answer
You might look at the YRBS (Youth Risk Behavior Survey) to obtain items.  Using these items would allow you to compare your intervention group to the youth in the state in which you are conducting the intervention. 
  • asked a question related to Cancer Prevention
Question
4 answers
I am about to dig myself into & conduct a research on health marketing, more specifically health-consciousness & prevention in general. I would be more than happy to know which the top relevant papers in this field are. What is the best scale to measure health-consciousness & prevention in general?
I will do my research in Hungary. Should you be interested to collaborate to compare research findings in different countries/cultures, please let me know.
Thanks in advance.
Relevant answer
Answer
You may look for a validated scale developed by Gould (1990). 
Gould SJ (1990) Health consciousness and health behavior: the application of a new health consciousness scale. American journal of preventive medicine, Department of Marketing, Rutgers, State University of New Jersey, New Brunswick 08903. 6(4): 228–237.
Here are some more articles that you may use to modify/adapt health consciousness scale.
  • Kaskutas, Lee A., and Thomas K. Greenfield. "The role of health consciousness in predicting attention to health warning messages." American Journal of Health Promotion 11.3 (1997): 186-193.
  • Jayanti, Rama K., and Alvin C. Burns. "The antecedents of preventive health care behavior: An empirical study." Journal of the Academy of Marketing Science 26.1 (1998): 6-15.
  • Moorman, Christine, and Erika Matulich. "A model of consumers' preventive health behaviors: The role of health motivation and health ability." Journal of Consumer Research (1993): 208-228.
  • Hong, Hyehyun. "Scale development for measuring health consciousness: Re-conceptualization." 12th Annual International Public Relations Research Conference, Holiday Inn University of Miami Coral Gables, Florida. 2009.
Hope they help.
  • asked a question related to Cancer Prevention
Question
2 answers
I am working on a research project and need
Breast Cancer Database of Younger and Older Women to determine MODIFIABLE RISK FACTORS for Breast Cancer Prevention, with following attributes:
Patient Age, Breast Cancer Sub-type, Age at Menarche, Body Weight, Peak Height Growth Velocity, Alcohol Intake, Physical Activity, Genetic Factors.
 
Relevant answer
Answer
Cancer incidence data set at small geographical units are exteremely difficult to get access to in the USA. Cancer registries make it very difficult, if not impossible, unless you are an epidemiologist who happens to work with the Department of Health on some project.
  • asked a question related to Cancer Prevention
Question
11 answers
I would be interested to hear from oncologists if they tell their patients to take vitamin D supplements and if so how much. 
There is a great deal of data suggesting Vitamin D would be useful in both cancer prevention and treatment.  There is actually quite a good summary of the data at www.vitaminD3world.com  It would appear that definitive prospective studies with Vitamin D in the major cancers have still not been conducted.  High dose versus low dose Vitamin D in advanced breast, colon and lung cancer would probably be the quickest way to demonstrate benefits.  Would be interested to hear thoughts on this
Relevant answer
Answer
Indeed. This paper reported significantly increased survival rates for those with higher 25-hydroxyvitamin D concentrations at time of cancer diagnosis for several types of cancer: Tretli S, Schwartz GG, Torjesen PA, Robsahm TE. Serum levels of 25-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 2012;23(2):363-70.
We have suggested that African-Americans have poorer cancer survival rates than white Americans due to lower 25OHD concentrations:  Grant WB, Peiris AN. Differences in vitamin D status may account for unexplained disparities in cancer survival rates between African and White Americans. Dermatoendocrinol. 2012;4(2): 85-94.
It may be that physicians are afraid to prescribe vitamin D to cancer patients since doing so has not been approved in general due to lack of clinical trials.
  • asked a question related to Cancer Prevention
Question
3 answers
We would like to give our mice a clinically relevant treatment of 5-Fluorouracil rather than the single 150mg/kg that seems to be more std with mice. However a conversion of a 5 day treatment for colon cancer in the clinic works out to giving the mice 132mg/kg per day for 5 days, which seems to me like it would be lethal. I am struggling to find access to literature on this (the paper below seems perfect but don't have access), does anyone have any information that could help us plan this experiment? Thank you. 
Relevant answer
Answer
Con'td: once you have set up the administration mode (and once again I strongly encourage you to choose the subcuntaneous continuous perfusion - beware, take the smalest osmotic pumps available (even if Alzet claims that bigger ones can fit into 25 g mice, it's just weird)), and next  just make a basic translation from human-to-mice dosing by considering that a normal 70 kg adult is about 1.73 m² (obviously this is quite variable, but this will give you the range) - depending on the mg/m² dosing  of the 5-FU regimen you are referring to in patients (quite variable as well, depending the protocol), then you can translate into mice eventually.  I have not made the calculations, but 132 mg/kg a day for 5 days by direct injection looks quite high indeed - having said that, switching to continuous infusion may improve the tolerance. Good luck!
  • asked a question related to Cancer Prevention
Question
8 answers
According to the National Cancer Institute, the FDA has approved two types of vaccines to prevent cancer: vaccines against the hepatitis B virus, which can cause liver cancer, and vaccines against human papillomavirus types 16 and 18, which are responsible for about 70 percent of cervical cancer cases. The FDA has also approved one cancer treatment vaccine for men with metastatic prostate cancer. Perhaps this could be more general and effective at lower costs than some other prevention and treatments - what are your thoughts?
Relevant answer
Answer
Thank you very much, Andrey! Very interesting reports! Great results! 
Concerning therapeutic vaccines (this term covers very wide range of therapeutics, stimulating antitumor immunity) I would say that we ever will see autoimmune disorders as backside effects. Key question here is the antigen which is used as a target for immune system. The situations when we can direct immune response to really tumor-specific antigen are too rare, for example, monoclonal products (Igs or TCRs) expressed by certain lymphomas or incorrectly glycosylated proteins on the surface of epithelial cancer cells. General rule is autoantigen expressed "at the wrong time and wrong place". However, adaptive immune system has been trained not to recognize or react weakly to these antigens. Using transgenic TCRs and CARs allows to induce strong immune response to these antigens, but to some extent increases risk for severe autoimmune disorders. In any case this requires to use highly personalized approache to therapy.
  • asked a question related to Cancer Prevention
Question
3 answers
looking for validated survey to examine factors that enable and impede breast cancer screening as well as measure breast cancer and prevention knowledge.
Relevant answer
Answer
thank you Michele. This is helpful. I did however wanted to use some validated existing scales in addition to making up some questions. Any recommendations for validated scales?
  • asked a question related to Cancer Prevention
Question
8 answers
It is now generally agreed that aspirin reduces the overall risk of both getting cancer and dying from cancer. This effect is particularly beneficial against colorectal cancer.  Some studies have concluded that the benefits are greater than the risks of aspirin induced bleeding in those at average risk. However, other studies were unclear if the benefits are greater than the risk. Both aspirin which is a cyclooxygenase inhibitor and clopidogrel which is an adenosine diphosphate receptor inhibitor are antiplatelet agents.  Is there any evidence that clopidogrel may be useful in cancer prevention?
Relevant answer
Answer
Sayed:
The several contributors above have already provided some valuable feedback on the issue raised in Sayed's excellent question, so I will restrict my attention to a brief summary of an internal review I recently completed on this theme in which I marshal evidence, including RCT human clinical data, that suggests a clinically relevant potential anticancer benefit from the addition of antiplatelet therapy to oncotherapy, distinct and independent from any anti-COX-2 inhibitory activity, showing that the anticancer benefit is leveraged via inhibition as well as a pro-apoptotic effect, its own set of unique molecular pathways apart from COX (se below). These lines of evidence find the clearest case for benefit stemming from the specific antiplatelet agents and ticlopidine (Ticlid(e) and especially defibrotide (Defitelio, Gentium), and provide motivation for a general class effect from antiplatelets (note: we have no robust data to date specifically for clopidogrel, which I would speculate may be compromised in studies due to adverse pharmacokinetics across the CYP2C19 hepatic enzyme within the P450 Cytochrome system).
I should note at the onset that, although one systematic review of standard-of-care treatment for bladder cancer failed to find any significant difference in recurrence-free survival rates following antiplatelet administration1, all the component seven studies reviewed exhibited important methodological limitations, and the aggregate data to date when systematically reviewed and critically appraised contradict these findings (see below):
Preclinical Motivation and Support
First, we know that antiplatelet drugs possess antineoplastic properties in vitro in a variety of malignancy types2,3 via a time and dose-dependent apoptotic effect on cancer cells. The molecular motivation also stems in significant part the fact that tumor cell-induced platelet aggregation (called TCIPA) is a significant contributor to and enabler of hematogenous metastasis, so that pretreatment with antiplatelet therapy significantly inhibits TCIPA, helping to interrupt the cancer metastasis cascade (during hematogenous dissemination, the interaction of circulating tumor cells (CTCs) with platelets via TCIPA is believed to promote tumor cell survival within the circulation4 with considerable preclinical data in support5,6, via in part as the data shows, by inhibition of three major platelet activation pathways, glycoprotein (GP)-Ib-IX, GPIIb/IIIa, and adenosine diphosphate (ADP)7 implicated in the promotion of tumor metastases.
Human Clinical Evidence
But beyond these preclinical studies, we also have human clinical data to support a clinically relevant anticancer benefit by the addition of antiplatelet therapy. In one study that examined the impact of antiplatelet treatment on colorectal cancer staging characteristics8, it was found that the mean tumor, node and metastasis stage was 2.57 for the control group compared to 2.27 for the antiplatelet group, with the incidence of advanced disease (stage IV) being significantly lower for the antiplatelet group of the study.
Furthermore, a randomized controlled trial (RCT)9 of the influence of antiplatelet drugs on the efficacy of combined antiplatelet plus standard oncotherapy (fixed chemotherapy plus radiotherapy) of small cell lung cancer (SCLC) which evaluated objective response rates, time to remission, and patient survival found that patients on antiplatelet therapy - defibrotide (Defitelio, Gentium) or ticlopidine (Ticlid(e) - had:
(1) 100% objective response (complete response (CR) plus partial response (PR)) compared to 46.7% in the aspirin treated group, with 9.5% in patients treated with aspirin compared to 68% in group of patients treated with the antiplatelet defibrotide;
(2) average remission time varied from 27.5 weeks in the control group to 50 weeks in patients treated with defibrotide;
(3) median overall survival time was 36.5 weeks within the control group and 53 weeks in the groups treated with addition of antiplatelet therapy; thus patients treated with the combined chemotherapy + antiplatelets had 1.5 fold greater probability of survival as compared with controls, with the longest survival above 4 years observed in the group of patients treated with addition with defibrotide.
Conclusions
These human clinical studies, along with the strong molecular support found within multiple preclinical studies, collectively support the plausibility of a clinically significant anticancer benefit from antiplatelet therapies, and future studies should help clarify the most effective agents and their optimal deployment, and validate the positive benefit/harm ratio (no significant safety signals were raised in the human clinical studies, including the RCT).
References
  1. Yuge K, Kikuchi E, Tanaka N, et al. Clinical impact of anti-platelet medication in patients with non-muscle invasive bladder cancer treated with BCG therapy. Urology. 2012;80:S218.
  2. Chen WH, Yin HL, Chang YY, Lan MY, Hsu HY, Liu JS. Antiplatelet drugs induce apoptosis in cultured cancer cells. Kaohsiung J Med Sci 1997; 13(10):589-97.
  3. Calvisi DF. Inhibition of hepatitis B virus-associated liver cancer by antiplatelet therapy: a revolution in hepatocellular carcinoma prevention? Hepatology 2013; 57(2):848-50.
  4. Egan K, Crowley D, Smyth P, O’Toole S, Spillane C, Martin C, Gallagher M, Canney A, Norris L, Conlon N, et al: Platelet adhesion and degranulation induce pro-survival and pro-angiogenic signalling in ovarian cancer cells. PloS One. 6:e261252011.
  5. Gasic GJ, Gasic TB, Galanti N, Johnson T, Murphy S: Platelet-tumor-cell interactions in mice. The role of platelets in the spread of malignant disease. Int J Cancer. 11:704–718. 1973.
  6. Honn KV: Inhibition of tumor cell metastasis by modulation of the vascular prostacyclin/thromboxane A2 system. Clin Exp Metastasis. 1:103–114. 1983.
  7. Lian L, Li W, Li ZY, et al. Inhibition of MCF-7 breast cancer cell-induced platelet aggregation using a combination of antiplatelet drugs. Oncol Lett 2013; 5(2):675-680.
  8. Symeonidis D, Koukoulis G, Christodoulidis G, Mamaloudis I, Chatzinikolaou I, Tepetes K. Impact of antiplatelet treatment on colorectal cancer staging characteristics. World J Gastrointest Endosc 2012 Sep 16; 4(9):409-13.
  9. Ochmański W. [Influence of antiplatelet drugs (AD) on the effectiveness of combined therapy of small cell lung cancer. Part II. Influence of treatment on time of remission and patients survival]. Przegl Lek 2008; 65(7-8):321-8.
  • asked a question related to Cancer Prevention
Question
2 answers
Is there a 'gold standard' model that is more predictive than others? Strengths vs. weaknesses of the various models?
Relevant answer
Answer
John:
If we examine the cumulative evidence to date using the various leading models of APC, AOM, MNU, BMBDD, MMR,TGF-b, xenograft, and the non-murine zebrafish, models of human colorectal cancer (CRC) disease, then the orthotopic model (especially orthotopic implantation) has the advantage of closely mimicking human CRC including tumor microenvironment [1,2,3,4;10]. It recapitulates all of the critical components of the tumor microenvironment, as well as all of the angiogenic factors, growth factors, and cytokines, thus finely mimicking the human CRC in terms of both metastasis and microenvironments, allowing evaluation of the alterations in and modulations of the microenvironment on tumorigenesis and progression [4].
Thus, Japanese investigators [8] evaluated the efficacy of anti-human VEGF antibody (bevacizumab) with or without irinotecan (CPT-11) postoperative adjuvant therapy against lung metastases in which neovascularization was already induced using orthotopically implanted colon cancer in rat, and the results from orthotopic-implantation tumor model suggested that a higher efficacy may be expected when bevacizumab is combined with the cytotoxic agent irinotecan (CPT-11), compared to bevacizumab monotherapy, and this has indeed been clinically confirmed [8]. In contrast, the xenograft model fails to represent the CRC tumor microenvironment, and with potential divergence of signaling pathways between its model and human disease [5,6,7].
These facts lead to a well-evidenced principle: that drugs that modulate the tumor microenvironment and the tumor-host interaction - as do so many oncologic agents - must be studied in orthotopic models [9], and recently these models have been extended and refined into sophisticated GEMM-derived orthotopic transplant models of Kras-mutant colorectal cancer for high-throughput drug discovery screening and candidate drug validation [11].
REFERENCES
1. Tseng, W.; Leong, X. & Engleman, E. (2007). Orthotopic mouse model of colorectal cancer. J Vis Exp, 484.
2. Pocard M, Tsukui H, Salmon RJ, Dutrillaux B, Poupon MF: Efficiency of orthotopic xenograft models for human colon cancers. In Vivo 1996; 10:463–469.
3. Wilmanns C, Fan D, O’Brian CA, Bucana CD, Fidler IJ: Orthotopic and ectopic organ environments differentially influence the sensitivity of murine colon carcinoma cells to doxorubicin and 5-fluorouracil. Int J Cancer 1992;52:98–104.
4. Suman S, Fornace AJ, Datta K. Animal Models of Colorectal Cancer in Chemoprevention and Therapeutics Development, Colorectal Cancer - From Prevention to Patient Care, 2012. Dr. Rajunor Ettarh (Ed.), ISBN: 978-953-51-0028-7, InTech.
5. Furukawa T, Kubota T, Watanabe M, et al. A metastatic model of human colon cancer constructed using cecal implantation of cancer tissue in nude mice. Surg Today, 1993; 23, 420-423. 2. Fidler, IJ. New developments in in vivo models of neoplasia. Cancer Metastasis 1991; Rev, 10, 191-192.
6. Fidler, IJ. Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis. Cancer Metastasis Rev 1991; 10, 229-243.
7. Fidler, IJ. (1991c). The biology of cancer metastasis or, 'you cannot fix it if you do not know how it works'. Bioessays 1991; 13, 551-554.
8. Mizobe, T.; Ogata, Y.; Murakami, H, et al. Efficacy of the combined use of bevacizumab and irinotecan as a postoperative adjuvant chemotherapy in colon carcinoma. Oncol Rep 2008; 20, 517-523.
9. Heijstek MW, Kranenburg O, Borel Rinkes IH. Mouse models of colorectal cancer and liver metastases. Dig Surg 2005; 22(1-2):16-25.
10. Rajput A, Agarwal E, Leiphrakpam P, Brattain MG, Chowdhury S.Establishment and Validation of an Orthotopic Metastatic Mouse Model of Colorectal Cancer. ISRN Hepatology 2013. Article ID 206875.
11. Martin ES, Belmont PJ, Sinnamon MJ, et al. Development of a colon cancer GEMM-derived orthotopic transplant model for drug discovery and validation. Clin Cancer Res 2013 Jun 1; 19(11):2929-40.
  • asked a question related to Cancer Prevention
Question
3 answers
African
Relevant answer
Answer
Yes, but with rigorous follow up and with a low threshold to start active treatment
  • asked a question related to Cancer Prevention
Question
3 answers
HIFU as fairly a new technology in the field of therapy using sonography.
Relevant answer
Answer
HIFU for Prostate Cancer is known since 1993. Today about 25.000 men had HIFU.
HIFU is able to appky focal treatment, that means organ sparing. Therefore one can hope that side-effects are lower if comparing with whole gland treatment
  • asked a question related to Cancer Prevention
Question
30 answers
70% or more of women in LMICs present with late stage breast cancer (BC). Most of those are ER-BC which occurs at a younger age and therefore in more dense breasts. Due to dense breasts, and of course, lack of resources, mammography is out of the question.
That leaves us with clinical breast exam (CBE) and breast self-exam (BSE), both of which are not known to reduce mortality. However, both can potentially downstage disease, CBE being better than BSE. So does that leave CBE as the only option for early detection and/or screening for BC in LMICs?
Relevant answer
Answer
Mobile digital mammography equipment and centralized radiology suite is probably the most easy to organize and cost/benefit effective in LMICs. However it is a usually political problem, not clinical.
  • asked a question related to Cancer Prevention
Question
46 answers
Many possibilities have been proposed, but what do you suggest to do in subjects with the tendevcy to develop recurrent polyps?
Relevant answer
Answer
Indded, few studies have examined the possibility of using 5ASA molecules for colorectal cancer prevention even outside inflammatory bowel diseases:
Aliment Pharmacol Ther. 2010 Jan 15;31(2):202-9. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Lyakhovich A, Gasche C.
Dig Dis Sci. 2009 Nov;54(11):2488-96. Chemoprevention of colonic polyps with balsalazide: an exploratory, double-blind, placebo-controlled study. Terdiman JP, Johnson LK, Kim YS, Sleisenger MH, Gum JR, Hayes A, Weinberg VK, McQuaid KR.
Mesalazine has the advantage of avoiding side effects of aspirin on upper and lower gastrointestinal tract and its use has been extended to colon inflammatory condition other than Crohn's and colitis, i. e. diverticular disease. Its chemopreventive effects is a debated problem in literature even if mainly confined to ulceratve colitis. However, basic science studies support its anti-carcinogenetic effect. So it will be possible that mesalzine may be useful for intestinal cancer prevention also in selected populations outside inflammatory bowel diseases.
  • asked a question related to Cancer Prevention
Question
1 answer
We are working on cancer prevention using neuroblastoma cells. Neuroblastoma cell lines include: substrate-adherent (S), neuroblastic (N) and internediate (I) cell types on which we usually do our experiments. But how can we resolve the use of control cell lines to ensure that the drug has/has not any side effects in normal cells?
Relevant answer
Answer
Try IPS cells instead.
  • asked a question related to Cancer Prevention
Question
6 answers
I am involved in a community based cancer awareness, early diagnosis and treatment programmes in India. We are in the process of redesigning the whole programme. Does anybody know of ongoing community based cancer prevention and control programmes from where I can obtain inputs for our programme?
Relevant answer
Answer
Try National Breast and Cervical Cancer Screening Program http://www.cdc.gov/cancer/nbccedp/about.htm
  • asked a question related to Cancer Prevention
Question
1 answer
I do a literature study about Immunologic characteristics and vaccination of colon cancer. Can someone give information about Biobase. Is Biobase available for isolated research ?
Relevant answer
Answer
I recommend to try elsevier Biobase
see also this link
you can find cancer specific Biobanks here also, if interested